EXCLUSIVE: 180 Life Sciences Identifies New Patentable CBD Analog For Drug Development For Treating Inflammation, Pain
180 Life Sciences Corp. (NASDAQ: ATNF) has identified a new synthetic CBD analog that is non-psychoactive and could have benefits in the reduction of inflammation and pain, the company announced on Wednesday.
